Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Dabigatran safety confirmed in real-world study

Pearl Toh
25 Apr 2018

Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.     

In the first analysis involving 4,873 patients (mean age 70.2 years, 55.6 percent male) with new-onset AF, patients were prescribed dabigatran 150 mg (55 percent), 110 mg (43 percent), or 75 mg (2 percent) for a mean duration of 18.3 months. [EHRA 2018, abstract 1055]

Over 2 years of follow-up, event rates for stroke and major bleeding were low with dabigatran, at 0.65 percent and 0.97 percent, respectively. The findings are consistent with data from other real-world studies, as well as randomized clinical trials such as the RE-LY** EU label analysis which showed a 1.10-percent stroke rate and 3.02-percent major bleeding rate with dabigatran. [Circulation 2015;131:157-164; Thromb Haemost 2014;111:933-942]

Rates of other clinical outcomes such as vascular death (0.85 percent) and life-threatening bleeds (0.46 percent) were also low.

“These prospective data from routine clinical care confirm the sustained safety and effectiveness of dabigatran over 2 years of follow-up … which is reassuring for physicians treating patients with AF,” according to study principal investigator Dr Gregory Lip from University of Birmingham, UK.

According to Lip, the GLORIA-AF study is currently ongoing and the phase III analysis of the programme will provide comparative data on the safety and efficacy of NOACs vs vitamin-K antagonists in the real world.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” he added.

Another analysis of the GLORIA-AF phase II programme included 4,859 patients (mean age 67.2 years, 64.5 percent male) who had been prescribed dabigatran for a mean duration of 18.3 months, of which 332 patients underwent 412 CV interventions with uninterrupted dabigatran. CV interventions included cardioversions (n=299), catheter ablations (n=38), pacemaker implantations (n=25), angiographic procedures (n=26), and angioplasty with or without stenting or catheter-based interventions (n=24). [EHRA 2018, abstract 200]

A mean follow-up of 7.52 weeks showed low rates of stroke/systemic embolism and major bleeds, occurring once each out of 412 interventions (risk, 0.25, 95 percent confidence interval, 0.01–1.36 for both events).

“The prospective analysis supports the favourable safety and effectiveness of dabigatran in clinical practice, complementing randomized trial data,” said Lip, citing the RE-CIRCUIT*** randomized controlled study which showed a 1.6 percent incidence rate of major bleeds during the 8 weeks after ablation. [N Engl J Med 2017;376:1627-1636]

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.